NeuroMetrix reported today that industry insiders got their first look at Quell during day 1 of this year’s International Consumer Electronics Show (CES).
Quell utilizes NeuroMetrix’s proprietary non-invasive neurostimulation technology to provide relief from chronic pain, particularly nerve pain such as due to diabetes and lower back problems. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. Users of the device will also have the option of using their smartphone to automatically track and personalize their pain therapy.
The response to Quell has been positive with PCWorld reporting, “Now there’s finally a consumer-grade wearable that’s designed to provide some relief.” CRN included Quell as one of “25 Hot Products at CES”. Interest from global retailers has been strong as the product brings a new level of benefit and relevance to the wearable technology category.
Consumers and medical professionals can now visit QuellRelief.com to learn more and sign up to receive information. The company expects to begin taking pre-orders for Quell in March and to ship during the second quarter. Quell will initially be available exclusively through doctor’s office and online.
“We were pleased with the response to Quell at CES. Clearly there is a need for wearable technology that makes a meaningful and clear difference in people’s lives,” said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix.
